Because the percentage of CD44+/CD24- cells in breast cancer cell lines does not predict tumorigenic potential, we next considered whether adding ESA to the repertoire of cell surface markers could enrich for tumor initiation capacity, as was previously demonstrated [2]. This evidence concerns the gene CD24 and breast cancer.